Literature DB >> 12077246

Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice.

Takashi Yahata1, Kiyoshi Ando, Yoshihiko Nakamura, Yoshito Ueyama, Kazuo Shimamura, Norikazu Tamaoki, Shunichi Kato, Tomomitsu Hotta.   

Abstract

An experimental model for human T lymphocyte development from hemopoietic stem cells is necessary to study the complex processes of T cell differentiation in vivo. In this study, we report a newly developed nonobese diabetic (NOD)/Shi-scid, IL-2Rgamma null (NOD/SCID/gamma(c)(null)) mouse model for human T lymphopoiesis. When these mice were transplanted with human cord blood CD34(+) cells, the mice reproductively developed human T cells in their thymus and migrated into peripheral lymphoid organs. Furthermore, these T cells bear polyclonal TCR-alphabeta, and respond not only to mitogenic stimuli, such as PHA and IL-2, but to allogenic human cells. These results indicate that functional human T lymphocytes can be reconstituted from CD34(+) cells in NOD/SCID/gamma(c)(null) mice. This newly developed mouse model is expected to become a useful tool for the analysis of human T lymphopoiesis and immune response, and an animal model for studying T lymphotropic viral infections, such as HIV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077246     DOI: 10.4049/jimmunol.169.1.204

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Homeostatic expansion and phenotypic conversion of human T cells depend on peripheral interactions with APCs.

Authors:  Takashi Onoe; Hannes Kalscheuer; Meredith Chittenden; Guiling Zhao; Yong-Guang Yang; Megan Sykes
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

2.  De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice.

Authors:  Paola Miyazato; Jun-ichirou Yasunaga; Yuko Taniguchi; Yoshio Koyanagi; Hiroaki Mitsuya; Masao Matsuoka
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

Review 3.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

4.  Induction and maintenance of IL-4 expression are regulated differently by the 3' enhancer in CD4 T cells.

Authors:  M Hanief Sofi; Yu Qiao; K Mark Ansel; Masato Kubo; Cheong-Hee Chang
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

Review 5.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

6.  Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.

Authors:  Kei Ohnuma; Ryo Hatano; Thomas M Aune; Haruna Otsuka; Satoshi Iwata; Nam H Dang; Taketo Yamada; Chikao Morimoto
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

Review 7.  Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.

Authors:  J Jason Morton; Gregory Bird; Yosef Refaeli; Antonio Jimeno
Journal:  Cancer Res       Date:  2016-09-01       Impact factor: 12.701

8.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

9.  Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells.

Authors:  Xinghui Tian; Melinda K Hexum; Vesselin R Penchev; Russell J Taylor; Leonard D Shultz; Dan S Kaufman
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

Review 10.  Use of humanized severe combined immunodeficient mice for human vaccine development.

Authors:  Gloria C Koo; Aisha Hasan; Richard J O'Reilly
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.